Latest / The Buyout Show with Fexingo: Private Equity, Roll-Ups, and Business Acquisitions / The Private Equity Roll-Up of Independent Optometry Clinics
Transcript
- Lucas: Let’s talk about your eyesight, literally. If you’ve had an eye exam in the last few years, you might have noticed that the independent optometry clinic down the street no longer feels quite as independent. Private equity firms are systematically rolling up fragmented optometry practices at a pace that is reshaping the entire sector. Luna: Right, it’s one of those healthcare sectors where you used to have mom and pop shops everywhere, but now you’re seeing chains popping up in suburbs they didn’t touch before. Lucas: Exactly. The driver here isn’t just vanity; it’s structural. With an aging population requiring more frequent vision checks and the rise of digital screens straining everyone’s eyes, demand has become sticky. But the real story is the margin expansion. By bundling hundreds of small clinics, PE firms can negotiate massive discounts on lenses and frames from manufacturers like EssilorLuxottica or Zeiss, something a single owner never could. Luna: So they are turning clinical care into a retail supply chain play? That sounds efficient, but does it change what the patient experiences? Lucas: It changes the back office entirely. These firms install centralized billing, standardized scheduling software, and uniform marketing funnels across every acquired location. They strip out the inefficiencies that plague solo practitioners, like underutilized equipment or inconsistent inventory management. It is classic operational leverage. Luna: That makes sense for profitability, but I worry about the doctor relationship. Are the optometrists staying, or are they being replaced by corporate managers? Lucas: They stay, but their role shifts. In many deals, the founding optometrist sells majority ownership but stays on as a clinician with a performance bonus tied to volume metrics. However, the strategic decisions—where to open new clinics, which frame brands to stock—are made centrally. It creates a tension between clinical autonomy and corporate efficiency that defines these roll-ups today. Luna: It reminds me of how dental labs were rolled up earlier this year. Is the playbook identical? Lucas: Very similar, though optometry has a higher barrier to entry because of the licensing requirements. You cannot just hire any manager to run an eye clinic. You need licensed optometrists, which makes talent retention critical. Firms are offering equity stakes to doctors who stay for five to seven years, effectively buying their loyalty alongside their book of patients. Luna: I see. So it’s less about firing doctors and more about aligning their financial incentives with the firm’s growth targets. Lucas: Precisely. And the capital markets love this model because it predicts recurring revenue. Unlike a hospital that might lose a contract, an optometry clinic has built-in patient recall systems. You get your glasses checked annually. That predictability allows PE firms to apply lower discount rates when valuing these assets compared to more volatile healthcare sectors. Luna: But what about insurance? If these firms start pushing proprietary lens brands or limiting network coverage, won’t patients push back? Lucas: That is the regulatory risk. Most major insurers still mandate broad networks, so firms cannot easily restrict choice without losing volume. However, some larger pe backed groups are beginning to launch their own standalone vision plans, bypassing traditional insurance altogether. This gives them full control over pricing and supplier contracts, creating a closed-loop ecosystem that is highly profitable if they can acquire enough members. Luna: A vertical integration move within their own portfolio. Smart, but risky if consumer trust erodes. Lucas: It is risky, but the trend is accelerating. We are seeing deal sizes grow significantly. What used to be acquisitions of single clinics are now portfolios of twenty to thirty locations per transaction. This scale allows for regional dominance, making it harder for remaining independents to compete on price or convenience. Luna: Do you think there is a ceiling to how much this market can consolidate before antitrust scrutiny kicks in? Lucas: Antitrust attention is growing, but healthcare roll-ups often fly under the radar until they reach a dominant market share in a specific metropolitan area. Regulators are watching, but the argument from these firms is always about improved access and quality through standardization. It is a tough battle to fight when the public generally prefers consistent, modern facilities over quirky independent ones. Luna: Fair point. Consumers do seem to value convenience and brand recognition now more than ever. Lucas: And let’s not forget the technology angle. These consolidated groups are faster to adopt ai driven retinal screening tools or automated refraction devices because they can spread the R&D cost across hundreds of sites. An independent doctor simply cannot justify that capital expenditure alone. Luna: So the tech advantage compounds the supply chain advantage. It becomes a moat that widens over time. Lucas: Exactly. It is a compounding effect. Better data leads to better inventory prediction, which lowers costs, which allows for competitive pricing, which attracts more patients, which generates more data. It is a virtuous cycle for the operator, but a challenging one for legacy players. Luna: This brings up an interesting question for listeners who might own such a practice. Is now the right time to sell? Lucas: For many, yes. The multiple on earnings in the optometry sector has expanded due to high demand from PE sponsors. Owners who built businesses over thirty years are finding buyers willing to pay premium multiples for stable cash flows. It is a rare moment where liquidity is abundant for this specific asset class. Luna: But only if the books are clean and the patient retention rates are strong. Messy finances would scare off those institutional investors. Lucas: Absolutely. Due diligence is rigorous. They look at churn rates, average ticket size per visit, and provider productivity. If a clinic is reliant on one star doctor or has outdated equipment, the valuation takes a hit. Preparation is key if you want to capture this window. Luna: It feels like the era of the purely independent small business in healthcare is narrowing rapidly. Lucas: It is narrowing, but not disappearing. There will always be niche providers serving specific communities or offering specialized care that doesn’t fit the standardized model. But for routine vision care, consolidation is the dominant force shaping the industry right now. Luna: We deliberately don't run ads on these. If you want to support that choice, the link is buy me a coffee dot com slash fexingo. Lucas: Yeah, it keeps the research deep and the commentary sharp without worrying about sponsor constraints. Thanks for helping us keep this independent. Luna: Back to the optics of the situation—literally. How do you see the labor market for optometrists shifting as these chains expand? Lucas: It is becoming more corporate. Entry-level optometrists may find themselves working in high-volume settings with stricter quotas. This could lead to burnout or a shift toward locum tenens work, where doctors travel between clinics. The job market is bifurcating between high-volume corporate roles and boutique private practices. Luna: That must be frustrating for newer grads who just want to practice medicine, not manage metrics. Lucas: It is. But the salary offers from pe backed firms are often higher due to signing bonuses and profit-sharing. Financial incentive usually wins out in the short term, even if job satisfaction varies. It is a trade-off we are seeing across many healthcare fields. Luna: Interesting. So the money moves one way, but the culture moves another. Lucas: Precisely. And as these firms mature, they will likely focus more on retention strategies to stabilize their workforce. High turnover kills the very efficiency gains they are trying to achieve. Luna: So it is a balancing act between scaling fast and keeping the people who actually deliver the service happy. Lucas: You nailed it. It is the classic growth vs. stability dilemma, played out in eye exams and glasses prescriptions. Luna: Does this consolidation affect the cost of contact lenses specifically, since those are often purchased online now? Lucas: It complicates it. Some PE groups have launched direct to consumer contact lens platforms to compete with Amazon and specialty retailers. They use their prescription data from physical exams to drive online sales, creating a hybrid model that captures value both in-office and at home. Luna: That is a clever way to extend the customer lifetime value beyond the annual check-up. Lucas: Exactly. It turns a once-a-year interaction into a monthly subscription revenue stream. That kind of predictable cash flow is music to a PE investor’s ears. Luna: I wonder if other healthcare fields will follow this exact blueprint soon. Maybe audiology or dermatology? Lucas: Dermatology is already moving in that direction, especially with cosmetic procedures. Audiology is next on the list given the hearing loss crisis among older adults. The playbook is ready; they just need the right target assets. Luna: So the template is set. Once one sector proves it works, the rest of healthcare gets rolled up too. Lucas: It seems that way. The question is whether the system can absorb that level of consolidation without losing the human element that makes healthcare effective in the first place. Luna: A valid concern. Efficiency matters, but empathy doesn’t scale as easily as supply chains. Lucas: True. And as these firms grow, they will have to figure out how to measure and incentivize empathy, not just volume. That might be the next frontier in their operational strategy. Luna: If they can crack that code, they will dominate the sector for decades. If not, the backlash could be significant. Lucas: It will be fascinating to watch how they adapt. For now, the momentum is firmly with the consolidators. Luna: Agreed. As long as the lights stay on and the glasses come out clear, most patients might not even notice the corporate hand behind the counter. Lucas: Perhaps. But for those of us tracking the deals, the pattern is unmistakable. The landscape is changing, and the winners will be those who master both the science of care and the art of scale.